ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript

ACADIA Pharmaceuticals Inc. ( ACAD ) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis September 24, 2026 8:00 AM EDT Company Participants Albert Kildani - Senior Vice President of Investor Relations & Corporate Communications Catherine Owen Adams - CEO & Director Elizabeth Thompson - Executive VP and Head of Research & Development Conference Call Participants Ritu Baral - TD Cowen, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Sumant Kulkarni - Canaccord Genuity Corp., Research Division Ashwani Verma - UBS Investment Bank, Research Division Nevin Varghese - RBC Capital Markets, Research Division Malcolm Hoffman - BMO Capital Markets Equity Research Julian Hung Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Sean Laaman - Morgan Stanley, Research Division Samuel Beck - Deutsche Bank AG, Research Division Basma Radwan Ibrahim - Leerink Partners LLC, Research Division Guofang Li - Wolfe Research, LLC Ami Fadia - Needham & Company, LLC, Research Division Eddie Hickman - Guggenheim Securities, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals conference call to discuss the RADIANT Phase II top line results evaluating Remlifanserin for the treatment of Alzheimer's disease psychosis. My name is Christa, and I will be your coordinator for today. I would now like to turn the presentation over to Al Kildani, Senior Vice President of Investor Relations and Corporate Communications. Please go ahead. Albert Kildani Senior Vice President of Investor Relations & Corporate Communications Thank you, Christa. Good morning, and thank you for joining us on today's call to discuss the top line results from the Phase II portion of our ongoing RADIANT clinical trial program evaluating Remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis or ADP. On today's call, Catherine Owen Adams, our Chief Executive Officer, will provide opening remarks. Following Catherine, Liz